Subcutaneous (SbQ) Versus Intravenous (IV) Administration of Amifostine for Head and Neck (HN) Cancer Patients Receiving Radiotherapy (RT): Preliminary Results of the GORTEC 2000-02 Randomized Trial

Reviewer: Charles Wood, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 19 de octubre del 2005

Translation for this article does not exist


Catherine and Finn
by OncoLink Editorial Team
December 01, 2015